Staar Surgical CO 8-K filings

STAAR Surgical Company announced robust second quarter 2026 financial results, featuring a 111% year-over-year increase in net sales to $93.5 million and a significant swing to a net income of $8.1 million.

STAAR Surgical announces the permanent appointment of Warren Foust as CEO and details new executive compensation packages, including performance-based stock options tied to significant stock price hurdles.

STAAR Surgical Company announced adjustments to its Interim Co-CEO and CFO's compensation, including a base salary increase and a higher annual bonus target.

STAAR Surgical announced preliminary Q1 2026 net sales exceeding $90 million, a significant increase from the prior year, driven by strong performance in China and the Americas.

STAAR Surgical reported an 18.1% net sales increase in Q4 2025 and reduced net loss, signaling a turnaround after a challenging fiscal year marked by significant losses and strategic shifts.

STAAR Surgical Company announced the termination of its Chief Legal Officer and Corporate Secretary, Nathaniel Sisitsky, effective February 4, 2026, who will transition to a consulting role.

STAAR Surgical Company has appointed Warren Foust and Deborah Andrews as Interim Co-Chief Executive Officers following the departure of Stephen C. Farrell, initiating a global search for a permanent CEO.

STAAR Surgical Company announced significant changes to its Board of Directors, including a new Board Chair and the establishment of two new committees, effective January 15, 2026.

STAAR Surgical announces a significant board restructuring and CEO Stephen Farrell's departure, following a cooperation agreement with major shareholder Broadwood Partners.

STAAR Surgical Company announced the termination of its merger agreement with Alcon Research, LLC, following shareholder rejection of the merger proposal.

STAAR Surgical announced its intent to terminate the merger agreement with Alcon after failing to secure the necessary stockholder votes at a special meeting.

STAAR Surgical Company announced an amendment to its merger agreement with Alcon, increasing the cash consideration for shareholders to $30.75 per share.

STAAR Surgical Company announced the expiration of its go-shop period without receiving any competing acquisition proposals, validating its merger agreement with Alcon Inc.

STAAR Surgical Company has amended its merger agreement with Alcon, introducing a 30-day go-shop period and waiving termination fees for superior offers from qualified bidders.

STAAR Surgical Company announced its third quarter 2025 financial results, reporting increased net sales and gross margin, alongside details of its pending acquisition by Alcon Inc.

STAAR Surgical Company has postponed its special stockholder meeting to vote on the merger agreement with Alcon until December 3, 2025, citing ongoing discussions.

STAAR Surgical Company and Alcon Research, LLC have agreed to adjourn their special stockholder meeting for the merger vote until November 6, 2025.

STAAR Surgical announced preliminary third-quarter 2025 net sales of $94.7 million, up 6.9% year-over-year, primarily boosted by a prior China shipment payment, while new orders from China declined.

STAAR Surgical Company has supplemented its merger proxy statement with Alcon, addressing stockholder lawsuits and providing additional background on the transaction and financial analyses.

STAAR Surgical Company's Board unanimously recommends the $28.00 per share all-cash merger with Alcon, citing compelling value and significant standalone risks, while refuting Broadwood Partners' opposition.

STAAR Surgical reported a 55% year-over-year decline in second-quarter net sales to $44.3 million, primarily due to a planned reduction of channel inventory in China, resulting in a net loss of $(16.8) million.

Alcon has entered into a definitive merger agreement to acquire STAAR Surgical Company for $28 per share in cash, valuing STAAR at approximately $1.5 billion.

STAAR Surgical Company announced the appointment of Deborah Andrews as Chief Financial Officer and the formation of a new Capital Stewardship Committee to guide financial strategies, alongside a restructuring of its investor relations function.

STAAR Surgical Company announced that its shareholders approved the election of six directors, ratified the appointment of BDO USA, P.C. as independent auditors, and approved executive compensation on an advisory basis at its 2025 Annual Meeting.

STAAR Surgical Company reports a significant decline in Q1 2025 China sales due to distributor inventory consumption, while other key markets show positive growth, as the company implements a strategic turnaround plan.

STAAR Surgical's Board of Directors has authorized a $30 million share repurchase program, and the company has received regulatory approval in China for its EVO+ Toric Implantable Collamer Lens (EVO+ TICL).

STAAR Surgical's Q1 2025 results were significantly impacted by planned inventory reductions in China, leading to a substantial decrease in net sales and a withdrawal of the company's financial outlook.

STAAR Surgical announces the appointment of Louis E. Silverman to its Board of Directors, the upcoming departure of Aimee S. Weisner, and Wei Jiang's new role as a special strategic advisor for the Asia Pacific business.

STAAR Surgical announces a realignment of its leadership structure, including the appointment of Warren Foust as President and COO, to drive revenue growth and improve cost structure.

STAAR Surgical Company appoints Stephen C. Farrell as CEO, succeeding Tom Frinzi, and elects Elizabeth Yeu, M.D., as Board Chair, effective February 26, 2025.